Cannabis addiction treatment is a success in clinical trial

An experimental drug that boosts the brain’s own cannabis-like chemical may help reduce withdrawal symptoms and cannabis use in men who are dependent or have cannabis use disorder, a trial has shown. 

The findings, published in the Lancet Psychiatry journal, show for the first time that men with cannabis dependence or cannabis use disorder treated with the fatty acid amide hydrolase (FAAH) inhibitor PF-04457845 used less cannabis and experienced fewer withdrawal symptoms than those given a placebo. 

The treatment works by blocking FAAH, an enzyme that breaks down a principal natural endocannabinoid chemical in the brain called anandamide, which acts on brain cannabinoid receptors like cannabis does. 

Less FAAH means higher anandamide levels, which may potentially improve mood and reduce anxiety. 

The trial by Yale included 70 male cannabis users aged 18 to 55, who either got the treatment or a<p data-recalc-dims=... read more at: